The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells.
Marta PoźniakNatalia PorębskaMateusz Adam KrzyścikAleksandra Sokołowska-WędzinaKamil JastrzębskiMartyna SochackaJakub SzymczykMałgorzata ZakrzewskaJacek OtlewskiLukasz OpalinskiPublished in: Molecular medicine (Cambridge, Mass.) (2021)
Our results show that T-Fc-vcMMAE fulfills the key criteria for the successful cytotoxic drug carrier in a targeted approach against FGFR1-positive cancer cells. Furthermore, our data implicate that not solely expression level of the receptor, but rather its cellular trafficking should be taken into account for selection of suitable molecular targets and cancer models for successful ADC approach.
Keyphrases
- cancer therapy
- papillary thyroid
- poor prognosis
- drug delivery
- binding protein
- squamous cell
- electronic health record
- big data
- diffusion weighted
- emergency department
- diffusion weighted imaging
- squamous cell carcinoma
- long non coding rna
- machine learning
- computed tomography
- adverse drug
- childhood cancer
- deep learning
- contrast enhanced